Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

While lab tests and imaging can sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical examination and thorough patient history are the most valuable tools in identifying this disease. According to a new literature review from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the rate of false positives in laboratory evaluations and imaging studies meant to screen for juvenile arthritis makes their value limited.

3 Mar 2011

New PSA campaign to raise awareness about autoimmune diseases

The American Autoimmune Related Diseases Association Inc. has unveiled a multi-media public service/awareness campaign titled "We are 50 Million" to herald March 2011 as National Autoimmune Diseases Awareness Month.

2 Mar 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Specialty biopharmaceutical company Santarus, Inc.and biotech company Pharming Group NV today announced the receipt of a "refusal to file" letter from the U.S. Food and Drug Administration for the RHUCIN Biologics License Application submitted by Pharming.

28 Feb 2011

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

'Experience station' program offers rheumatologists to gain insight into patients' everyday challenges

Pharmaceutical companies are focusing on more unique approaches in the development of educational and experiential solutions for their health care customers at medical conferences, according to Joe Scrocco, chief executive officer of OneWorld, Inc., a leading pharmaceutical consulting firm.

21 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Chelsea prices underwritten public offering of 8.75 million shares of common stock

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of 8.75 million shares of its common stock at a price of $4.00 per share which will result in gross proceeds of $35 million.

18 Feb 2011

Bone remodeling inflammatory protein linked to metastatic lung cancer development in mice with breast cancer

When doctors discover high concentrations of regulatory T cells in the tumors of breast cancer patients, the prognosis is often grim, though why exactly has long been unclear.

16 Feb 2011

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera Pharmaceuticals, Inc. announced today that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters.

15 Feb 2011

'Real world' guidelines may effectively prevent cardiovascular disease in women

Practical medical advice that works in the "real world" may more effectively prevent cardiovascular disease in women than recommendations based only on findings in clinical research settings, according to the 2011 update to the American Heart Association's cardiovascular disease prevention guidelines for women.

15 Feb 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

New PSA campaign to raise awareness about autoimmune diseases

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

SQI Diagnostics first quarter net loss increases to $2,255,000

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Research sheds new light on problem of insulin resistance in type 2 diabetes

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

'Experience station' program offers rheumatologists to gain insight into patients' everyday challenges

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Chelsea prices underwritten public offering of 8.75 million shares of common stock

Bone remodeling inflammatory protein linked to metastatic lung cancer development in mice with breast cancer

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

'Real world' guidelines may effectively prevent cardiovascular disease in women

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in